Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles

Long-acting parenteral (LAP) antiretroviral drugs have generated considerable interest for treatment and prevention of HIV-1 infection. One new LAP is cabotegravir (CAB), a highly potent integrase inhibitor, with a half-life of up to 54 days, allowing for every other month parenteral administrations...

全面介紹

Na minha lista:
書目詳細資料
發表在:Biomaterials
Main Authors: Zhou, Tian, Su, Hang, Dash, Prasanta, Lin, Zhiyi, Shetty, Bhagya Laxmi Dyavar, Kocher, Ted, Szlachetka, Adam, Lamberty, Benjamin, Fox, Howard S., Poluektova, Larisa, Gorantla, Santhi, McMillan, JoEllyn, Gautam, Nagsen, Mosley, R. Lee, Alnouti, Yazen, Edagwa, Benson, Gendelman, Howard E.
格式: Artigo
語言:Inglês
出版: 2017
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5926202/
https://ncbi.nlm.nih.gov/pubmed/29059541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.biomaterials.2017.10.023
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍